Getting the dose right: Report from the tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 32, Issue 2, 2005, Pages 199-211

  Stanski, Donald R ^a   Rowland, Malcolm ^b   Sheiner, Lewis B ^c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dose; Drug development; Meeting report; Response

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST; BENZODIAZEPINE RECEPTOR AFFECTING AGENT;

CONFERENCE PAPER; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG RESPONSE; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; NONHUMAN; ORGANIZATION; PRIORITY JOURNAL; SIMULATION;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; EUROPE; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 28244484349     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-005-0010-x     Document Type: Conference Paper

References (16)

1. L.J. Lesko M. Rowland C.C. Peck T.F. Blaschke 2000 Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans Eur. J. Pharm. Sci. 10 iv xiv
2. P. Rolan A.J. Atkinson Jr L.J. Lesko 2003 Use of biomarkers from drug discovery through clinical practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development Clin. Pharmacol. Ther. 73 284 291
3. G.T. Tucker J.B. Houston S.W. Huang 2001 Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus Eur. J. Pharm. Sci. 13 417 428
4. Arlington S., S. Barnett, S. Hughes, and J. Palo. Pharma 2010: The Threshold of Innovation. IBM Business Consulting Services, 2002
5. J. Cross H. Lee Westelinck A.J. Nelson C. Grudzinkas C. Peck 2002 Post- marketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999 Pharmacoepidemiol. Drug Safety 11 439 446
6. L.B. Sheiner 1997 Learning vs. confirming in clinical drug development Clin Pharmacol. Ther. 61 275 291
7. Leiden/Amsterdam Center for Drug Research conferences in Noordwijkerhout, 1990, 1994, 1998, 2002
8. L.B. Sheiner J.L. Steimer 2000 Pharmacokinetic and pharmacodynamic modeling in drug development Ann. Rev. Pharmacol. Toxicol. 40 67 95
9. N.H.G. Holford H.C. Kimko J.P.R. Monteleone C.C. Peck 2000 Simulation of clinical trials Ann. Rev. Pharmacol. Toxicol. 40 209 234
10. http://www.fda.gov/cder/guidance/index.htm • ICH E-4: Dose-Response Information to Support Drug Registration (1994)
11. • Exposure Response Relationships: Study Design, Data Analysis and Regulatory Applications (2003)
12. • Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (1998)
13. S.A. Visser D.R. Huntjens P.H. van der Graaf L.A. Peletier M. Danhof 2003 Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats J. Pharmacol. Exp. Ther. 307 765 775
14. M. Danhof S.A. Visser 2002 and pharmacokinetic-pharmacodynamic modeling in drug development Methods Find. Exp. Clin. Pharmacol. 24 suppl D 127 128
15. M. Krams K.R. Lees W. Hacke A.P. Grieve J.M. Orgogozo G.A. Ford 2003 Acute stroke therapy by inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke Stroke 34 2543 2548
16. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf